Bismuth chelate as a contrast agent for X-ray computed tomography
Ji-jun Fu,Jun-jie Guo,Ai-ping Qin,Xi-yong Yu,Qiang Zhang,Xue-ping Lei,Yu-gang Huang,Ming-yue Chen,Jie-xia Li,Yu Zhang,Jing-ping Liu,Yuan-ye Dang,Dan Wu,Xiao-ya Zhao,Zhong-xiao Lin,Yin-lei Lin,Song-pei Li,Ling-yan Zhang
DOI: https://doi.org/10.1186/s12951-020-00669-4
IF: 10.2
2020-08-06
Journal of Nanobiotechnology
Abstract:Abstract Backgrounds Due to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time—consuming. Methods In this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent. Results The preparation method is easy and cost—effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 μM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first—order elimination kinetics and, it has a short half—life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility. Conclusions This bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.
biotechnology & applied microbiology,nanoscience & nanotechnology